1.Bacigalupo, A, Socié, G, Schrezenmeier, H, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica. 2012;97(8):1142–8.
2.Bacigalupo, A, Brand, R, Oneto, R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy–The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37(1):69–80.
3.Ades, L, Mary, JY, Robin, M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004;103(7):2490–7.
4.Schrezenmeier, H, Passweg, JR, Marsh, JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110(4):1397–400.
5.Stern, M, Passweg, J, Locasciulli, A, et al. Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation. Transplantation. 2006;82(2):218–26.
6.Bacigalupo, A, Socie, A, Hamladji, RM, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia. Haematologica. 2015;100:696–702.
7.Maury, S, Bacigalupo, A, Anderlini, P, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94(9):1312–5.
8.Locatelli, F, Bruno, B, Zecca, M, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96(5):1690–7.
9.Maury, S, Balere-Appert, ML, Chir, Z, et al. French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica. 2007;92:589–96.
10.Viollier, R, Socié, G, Tichelli, A, et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant. 2008;41(1):45–50.
11.Bacigalupo, A, Marsh, JC. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18–40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant. 2013;48(2):198–200.
12.Marsh, JC, Gupta, V, Lim, Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia Blood. 2011;118(8):2351–7
13.Samarasinghe, S, Steward, C, Hiwarkar, P, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol. 2012;157(3):339–46.
14.Eapen, M, Rademacher, JL, Antin, JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood 2011;118:2618–21.
15.Deeg, HJ, Amylon, ID, Harris, RE, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant. 2001;7:208–15.
16.Tolar, J, Deeg, HJ, Arai, S, Horwitz, M, et al. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant. 2012;18(7):1007–11.
17.Kojima, S, Matsuyama, T, Kato, S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100:799–803.
18.Shimada, A, Takahashi, Y, Muramatsu, H, et al. Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen. Int J Hematol. 2012;95(6):675–9.
19.Peffault de Latour, R, Rocha, V, Socié, G. Cord blood transplantation in aplastic anemia. Bone Marrow Transplant. 2013;48(2):201–2.
20.Peffault de Latour, R, Purtill, D, Ruggeri, , et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by Eurocord and the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2010;1:78–85.
21.Reisner, Y, Hagin, D, Martelli, MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood. 2011;118(23):6006–17.
22.Luznik, L, O’Donnell, PV, Fuchs, EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):683–93.
23.Ciceri, F , Lupo-Stanghellini, MT, Korthof, ET, on behalf of the SAA-WP EBMT. Haploidentical transplantation in patients with acquired aplastic anemia. Bone Marrow Transplant. 2012;48:183.
24.Clay, J, Kulasekarara, AG, Potter, V, et al. Non-myeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2014;20(11):1711–6.
25.Xu, LP, Liu, KY, Liu, DH, et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant. 2012;47(12):1507–12.
26.Peffault de Latour, R, Schrezenmeier, H, Bacigalupo, A, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica. 2012;97(11):1666–73.
